NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.
PEPTONIC medical AB (“Peptonic” or the “Company”) today announces the outcome of the exercise of warrants of series TO4 (the “Warrants”). In total, 3,538,820 Warrants were exercised, corresponding to approximately 1.80 percent of the total number of outstanding Warrants, for subscription of 3,538,820 shares at a subscription price of SEK 0.028 per share. Peptonic will receive approximately SEK 0.1 million before issuing costs through the exercise of the Warrants.
The subscription rate for the exercise of warrants of series TO4 was anticipated, following the board’s decision on April 16, 2024, to conduct a Rights Issue of units aimed at supporting our international growth journey and the development of innovative products,” says Anna Linton, CEO of Peptonic. “The Rights Issue will run from May 28, 2024, to June 12, 2024.
The exercise period for exercise of the Warrants took place from and including April 17, 2024, up to and including May 1, 2024. The subscription price per share for exercising the Warrants was set to SEK 0.028. In total, 3,538,820 Warrants were exercised for subscription of, 3,538,820 shares, meaning that approximately 1.80 percent of all outstanding Warrants were exercised.
Exercised Warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Share capital and dilution
Through the exercise of the Warrants, the number of shares in Peptonic increases by 3,538,820 shares, from 1,534,845,596 shares to a total of 1,538,384,416 shares. The share capital will increase by approximately SEK 88,470.50 from approximately SEK 38,371,139.91 to approximately SEK 38,459,610.41.
For existing shareholders who did not exercise any Warrants, the dilution amounts to approximately 0.23 percent of the number of shares and votes in the Company.
Advisers
Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the utilization of the warrants of series TO4.
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About PEPTONIC medical AB
The company continuously aims to broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company’s mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio. Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners.
The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense in the USA and Peptonic Medical in Israel. Peptonic Medical was founded in 2009, and the company’s shares have been listed on the Spotlight Stock Market since 2014.
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
